ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
about
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesNovel anti-melanoma treatment: focus on immunotherapy.Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.
P2860
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ECOG phase II trial of graded- ...... broblast growth factor (E2602)
@en
ECOG phase II trial of graded- ...... basic fibroblast growth factor
@nl
type
label
ECOG phase II trial of graded- ...... broblast growth factor (E2602)
@en
ECOG phase II trial of graded- ...... basic fibroblast growth factor
@nl
prefLabel
ECOG phase II trial of graded- ...... broblast growth factor (E2602)
@en
ECOG phase II trial of graded- ...... basic fibroblast growth factor
@nl
P2093
P2860
P1476
ECOG phase II trial of graded- ...... broblast growth factor (E2602)
@en
P2093
Ahmad A Tarhini
Dean A Jobe
Donghoon Shin
John M Kirkwood
Robert M Conry
Ronald S Go
Sandra J Lee
Steven M Callister
P2860
P304
P356
10.1158/1078-0432.CCR-13-1414
P407
P577
2013-10-11T00:00:00Z